
Opinion|Videos|January 20, 2025
Patient Selection for Teplizumab and Infusion Process
Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
New ACS Guideline Endorses Self-Collected HPV Tests for Cervical Cancer Screening
2
Hepatitis B Foundation President Discusses ACIP Hepatitis B Birth Dose Recommendation
3
FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option
4
Lecanemab Data Suggest Sustained Delay in Alzheimer Disease Progression With Long-Term Maintenance Therapy
5






















































































































































































































































































